References
- . Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993;90(24):11693–11697
- . Ong CK, Lirk P, Tan CH, Seymour RA. An evidence-based update on non-steroidal anti-inflammatory drugs. Clin Med Res. 2007;5(1):19–34
- . Ku EC, Lee W, Kothari HV, Scholer DW. Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med. 1986;80(4B):18–23
- . Indomethacin [package insert]. Edison, NJ: Heritage Pharmaceuticals, Inc; July 2010
- . Naproxen [package insert]. Ingelheim, Germany: Boehringer Ingleheim, Roxane Laboratories; February 2010
- . Voltaren [package insert]. Basel, Switzerland: Novartis Pharmaceuticals Corp; February 2011
- . Gluszko P, Bielinska A. Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors? Pol Arch Med Wewn. 2009;119(4): 231–235
- . Borer JS, Simon LS. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Res Ther. 2005;7( suppl 4):S14–S22
- . Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54(3):320–326
- . US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. 2002. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126833.pdf. Accessed July 20, 2011
- . Bakshi R, Frenkel G, Dietlein G, Meurer-Witt B, Schneider B, Sinterhauf U. A placebo-controlled comparative evaluation of diclof, enac dispersible versus ibuprofen in postoperative pain after third molar surgery. J Clin Pharmacol. 1994;34(3):225–230
- . Bamber MJ, Tweedie IE, Breeze C, Williams NE. Premedication with controlled release diclofenac sodium reduces post-operative pain after minor gynaecological surgery. Eur J Anaesthesiol. 1997;14:421–427
- . Breivik EK, Barkvoll P, Skovlund E. Combining diclofenac with acetaminophen or acetaminophen-codeine after oral surgery: a randomized, double-blind single-dose study. Clin Pharmacol Ther. 1999;66(6):625–635
- . Hersh EV, Levin LM, Adamson D,. Dose-ranging analgesic study of Prosorb diclofenac potassium in postsurgical dental pain. Clin Ther. 2004;26(8):1215–1227
- . Matthews RW, Scully CM, Levers BG. The efficacy of diclofenac sodium (Voltarol) with and without paracetamol in the control of post-surgical dental pain. Br Dent J. 1984;157(10):357–359
- . Moore N. Diclofenac potassium 12.5 mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety. Clin Drug Investig. 2007;27:163–195
- . Cataflam [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; July 2005
- . Hinz B, Chevts J, Renner B,. Bioavailability of diclofenac potassium at low doses. Br J Clin Pharmacol. 2005;59(1):80–84
- . Macia MA, Frias J, Carcas AJ, Guerra P, Valiente R, Lucero ML. Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. Int J Clin Pharmacol Ther. 1995;33(6):333–339
- . Riad LE, Sawchuk RJ, McAlary MM, Chan KK. Effect of food on the multiple-peak behavior after a single oral dose of diclofenac sodium slow-release tablet in humans. Am J Ther. 1995;2(4):237–242
- . Terhaag B, Hoffmann A, Barkworth M, Vens-Cappell B. Bioavailability of a new effervescent tablet of diclofenac. Int J Clin Pharmacol Ther. 2000;38(11):546–551
- . Graham DJ, Campen D, Hui R,. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475–481
- . US Food and Drug Administration. Public health advisory—FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug-SafetyInformationforPatientsandProviders/ucm150314.htm. 2005. Accessed September 15, 2011
- . US Food and Drug Administration. FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108361.htm. 2004. Accessed September 15, 2011
- . FlectorPatch [package insert] Bristol, TN: King Pharmaceuticals, Inc; February 2011
- . VoltarenGel [package insert]. Basel, Switzerland: Novartis; October 2009